NZ779157B2 - Palatable formulations - Google Patents
Palatable formulations Download PDFInfo
- Publication number
- NZ779157B2 NZ779157B2 NZ779157A NZ77915720A NZ779157B2 NZ 779157 B2 NZ779157 B2 NZ 779157B2 NZ 779157 A NZ779157 A NZ 779157A NZ 77915720 A NZ77915720 A NZ 77915720A NZ 779157 B2 NZ779157 B2 NZ 779157B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- tablet
- total weight
- amount
- composition
- animal based
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 168
- 238000009472 formulation Methods 0.000 title description 3
- 239000003826 tablet Substances 0.000 claims abstract description 205
- 241001465754 Metazoa Species 0.000 claims abstract description 116
- 239000011230 binding agent Substances 0.000 claims abstract description 48
- 239000000796 flavoring agent Substances 0.000 claims abstract description 46
- 235000019634 flavors Nutrition 0.000 claims abstract description 45
- 239000000314 lubricant Substances 0.000 claims abstract description 44
- 239000007884 disintegrant Substances 0.000 claims abstract description 42
- 239000003906 humectant Substances 0.000 claims abstract description 39
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 33
- 239000003607 modifier Substances 0.000 claims abstract description 32
- 239000007910 chewable tablet Substances 0.000 claims abstract description 26
- 229940068682 chewable tablet Drugs 0.000 claims abstract description 24
- 201000008937 atopic dermatitis Diseases 0.000 claims abstract description 18
- 208000006673 asthma Diseases 0.000 claims abstract description 17
- 239000013543 active substance Substances 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 14
- 208000003251 Pruritus Diseases 0.000 claims abstract description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 12
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 12
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 12
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 11
- 230000007815 allergy Effects 0.000 claims abstract description 11
- 206010012438 Dermatitis atopic Diseases 0.000 claims abstract description 10
- 206010012434 Dermatitis allergic Diseases 0.000 claims abstract description 8
- 201000011510 cancer Diseases 0.000 claims abstract description 8
- 208000014085 Chronic respiratory disease Diseases 0.000 claims abstract description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerol group Chemical group OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 44
- VQIGDTLRBSNOBV-VQIYXBGXSA-N chembl2105739 Chemical compound OC(=O)\C=C/C(O)=O.C1C[C@@H](CS(=O)(=O)NC)CC[C@@H]1N(C)C1=NC=NC2=C1C=CN2 VQIGDTLRBSNOBV-VQIYXBGXSA-N 0.000 claims description 41
- 229960000393 oclacitinib maleate Drugs 0.000 claims description 30
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 26
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- -1 glidant Substances 0.000 claims description 20
- 239000002202 Polyethylene glycol Substances 0.000 claims description 17
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 17
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 17
- 229920001223 polyethylene glycol Polymers 0.000 claims description 17
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 15
- 229960000913 crospovidone Drugs 0.000 claims description 14
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims description 14
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims description 14
- 235000015277 pork Nutrition 0.000 claims description 14
- 210000004185 liver Anatomy 0.000 claims description 13
- 235000010493 xanthan gum Nutrition 0.000 claims description 13
- 239000000230 xanthan gum Substances 0.000 claims description 13
- 229920001285 xanthan gum Polymers 0.000 claims description 13
- 229940082509 xanthan gum Drugs 0.000 claims description 13
- HJWLJNBZVZDLAQ-HAQNSBGRSA-N chembl2103874 Chemical group C1C[C@@H](CS(=O)(=O)NC)CC[C@@H]1N(C)C1=NC=NC2=C1C=CN2 HJWLJNBZVZDLAQ-HAQNSBGRSA-N 0.000 claims description 12
- 229960004955 oclacitinib Drugs 0.000 claims description 12
- 239000008109 sodium starch glycolate Substances 0.000 claims description 12
- 229920003109 sodium starch glycolate Polymers 0.000 claims description 12
- 229940079832 sodium starch glycolate Drugs 0.000 claims description 12
- 235000019359 magnesium stearate Nutrition 0.000 claims description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 10
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 229940050929 polyethylene glycol 3350 Drugs 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 claims description 8
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 208000026935 allergic disease Diseases 0.000 claims description 3
- 206010003645 Atopy Diseases 0.000 claims description 2
- 239000007885 tablet disintegrant Substances 0.000 claims 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 4
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 2
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 abstract description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 14
- 235000011187 glycerol Nutrition 0.000 description 12
- 229940009192 apoquel Drugs 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 11
- 235000013372 meat Nutrition 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 150000002500 ions Chemical class 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 238000007906 compression Methods 0.000 description 9
- 230000006835 compression Effects 0.000 description 9
- 239000002552 dosage form Substances 0.000 description 9
- 238000005469 granulation Methods 0.000 description 9
- 230000003179 granulation Effects 0.000 description 9
- 238000002156 mixing Methods 0.000 description 9
- 239000004480 active ingredient Substances 0.000 description 8
- 241000283073 Equus caballus Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000007916 tablet composition Substances 0.000 description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000001363 autoimmune Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 238000001125 extrusion Methods 0.000 description 5
- 229940075507 glyceryl monostearate Drugs 0.000 description 5
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 235000019629 palatability Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000042838 JAK family Human genes 0.000 description 4
- 108091082332 JAK family Proteins 0.000 description 4
- 108010000837 Janus Kinase 1 Proteins 0.000 description 4
- 229920000881 Modified starch Polymers 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- 229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 4
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 4
- 241000282898 Sus scrofa Species 0.000 description 4
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- 238000005550 wet granulation Methods 0.000 description 4
- 241000251468 Actinopterygii Species 0.000 description 3
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 3
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 3
- 241000282465 Canis Species 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- 102000006503 Janus Kinase 2 Human genes 0.000 description 3
- 108010019437 Janus Kinase 2 Proteins 0.000 description 3
- 108010019421 Janus Kinase 3 Proteins 0.000 description 3
- 235000019687 Lamb Nutrition 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 3
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 235000013351 cheese Nutrition 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000019688 fish Nutrition 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 235000014102 seafood Nutrition 0.000 description 3
- 229940080313 sodium starch Drugs 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 description 2
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 2
- 206010013774 Dry eye Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000000305 astragalus gummifer gum Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 235000015111 chews Nutrition 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229960001681 croscarmellose sodium Drugs 0.000 description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 2
- 102000003675 cytokine receptors Human genes 0.000 description 2
- 108010057085 cytokine receptors Proteins 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 229960005205 prednisolone Drugs 0.000 description 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 2
- AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 description 2
- 239000000473 propyl gallate Substances 0.000 description 2
- 235000010388 propyl gallate Nutrition 0.000 description 2
- 229940075579 propyl gallate Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- FLEFKKUZMDEUIP-QFIPXVFZSA-N 1-[6-[(5s)-5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]spiro[1h-2-benzofuran-3,3'-azetidine]-1'-yl]-2-methylsulfonylethanone Chemical compound C1N(C(=O)CS(=O)(=O)C)CC21C1=CC=C(C=3C[C@](ON=3)(C=3C=C(Cl)C(F)=C(Cl)C=3)C(F)(F)F)C=C1CO2 FLEFKKUZMDEUIP-QFIPXVFZSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IPODSGLIYFREHI-UHFFFAOYSA-N 1-methylsulfonylethanone Chemical compound CC(=O)S(C)(=O)=O IPODSGLIYFREHI-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 description 1
- 125000004362 3,4,5-trichlorophenyl group Chemical group [H]C1=C(Cl)C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- YNSCKPCDFIDINW-UHFFFAOYSA-N 3-[[2-[[1-[2-(dimethylamino)acetyl]-6-methoxy-4,4-dimethyl-2,3-dihydroquinolin-7-yl]amino]-7h-pyrrolo[2,3-d]pyrimidin-4-yl]amino]thiophene-2-carboxamide Chemical compound COC1=CC(C(CCN2C(=O)CN(C)C)(C)C)=C2C=C1NC(N=C1NC=CC1=1)=NC=1NC=1C=CSC=1C(N)=O YNSCKPCDFIDINW-UHFFFAOYSA-N 0.000 description 1
- HDKWFBCPLKNOCK-SFHVURJKSA-N 3-methyl-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]-5-[(5s)-5-(3,4,5-trichlorophenyl)-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]thiophene-2-carboxamide Chemical compound S1C(C(=O)NCC(=O)NCC(F)(F)F)=C(C)C=C1C1=NO[C@](C(F)(F)F)(C=2C=C(Cl)C(Cl)=C(Cl)C=2)C1 HDKWFBCPLKNOCK-SFHVURJKSA-N 0.000 description 1
- OXDDDHGGRFRLEE-UHFFFAOYSA-N 4-[5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4h-1,2-oxazol-3-yl]-n-[2-oxo-2-(2,2,2-trifluoroethylamino)ethyl]naphthalene-1-carboxamide Chemical compound C12=CC=CC=C2C(C(=O)NCC(=O)NCC(F)(F)F)=CC=C1C(C1)=NOC1(C(F)(F)F)C1=CC(Cl)=CC(C(F)(F)F)=C1 OXDDDHGGRFRLEE-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 1
- CULUWZNBISUWAS-UHFFFAOYSA-N Benznidazole Chemical compound [O-][N+](=O)C1=NC=CN1CC(=O)NCC1=CC=CC=C1 CULUWZNBISUWAS-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000282836 Camelus dromedarius Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 229930105110 Cyclosporin A Natural products 0.000 description 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 229920003083 Kollidon® VA64 Polymers 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- XUIIKFGFIJCVMT-LBPRGKRZSA-N L-thyroxine Chemical compound IC1=CC(C[C@H]([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-LBPRGKRZSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000289581 Macropus sp. Species 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000002231 Muscle Neoplasms Diseases 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000014767 Myeloproliferative disease Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010036030 Polyarthritis Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 229920003080 Povidone K 25 Polymers 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- AQXXZDYPVDOQEE-MXDQRGINSA-N Pyrantel pamoate Chemical compound CN1CCCN=C1\C=C\C1=CC=CS1.C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 AQXXZDYPVDOQEE-MXDQRGINSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 1
- 206010048873 Traumatic arthritis Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 229940077422 accupril Drugs 0.000 description 1
- 229960005054 acepromazine Drugs 0.000 description 1
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 1
- 229940022663 acetate Drugs 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 229960000982 afoxolaner Drugs 0.000 description 1
- 230000010085 airway hyperresponsiveness Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 201000009961 allergic asthma Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960003683 amprolium Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 230000000842 anti-protozoal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940125687 antiparasitic agent Drugs 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 229940036589 antiprotozoals Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229960003159 atovaquone Drugs 0.000 description 1
- KUCQYCKVKVOKAY-CTYIDZIISA-N atovaquone Chemical compound C1([C@H]2CC[C@@H](CC2)C2=C(C(C3=CC=CC=C3C2=O)=O)O)=CC=C(Cl)C=C1 KUCQYCKVKVOKAY-CTYIDZIISA-N 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 229960004530 benazepril Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229960004001 benznidazole Drugs 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000002374 bone meal Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 208000000594 bullous pemphigoid Diseases 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229940041011 carbapenems Drugs 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000002327 cardiovascular agent Substances 0.000 description 1
- 229940125692 cardiovascular agent Drugs 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 229940045110 chitosan Drugs 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007596 consolidation process Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229960002806 daclizumab Drugs 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- WAZQAZKAZLXFMK-UHFFFAOYSA-N deracoxib Chemical compound C1=C(F)C(OC)=CC=C1C1=CC(C(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 WAZQAZKAZLXFMK-UHFFFAOYSA-N 0.000 description 1
- 229960003314 deracoxib Drugs 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 229960001894 detomidine Drugs 0.000 description 1
- JXMXDKHEZLKQPB-UHFFFAOYSA-N detomidine Chemical compound CC1=CC=CC(CC=2[N]C=NC=2)=C1C JXMXDKHEZLKQPB-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 208000024558 digestive system cancer Diseases 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- RMGVZKRVHHSUIM-UHFFFAOYSA-L dithionate(2-) Chemical compound [O-]S(=O)(=O)S([O-])(=O)=O RMGVZKRVHHSUIM-UHFFFAOYSA-L 0.000 description 1
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 description 1
- 229960003997 doramectin Drugs 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 208000024711 extrinsic asthma Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical group C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- FULAPETWGIGNMT-UHFFFAOYSA-N firocoxib Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OCC1CC1 FULAPETWGIGNMT-UHFFFAOYSA-N 0.000 description 1
- 229960002524 firocoxib Drugs 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- NOOCSNJCXJYGPE-UHFFFAOYSA-N flunixin Chemical compound C1=CC=C(C(F)(F)F)C(C)=C1NC1=NC=CC=C1C(O)=O NOOCSNJCXJYGPE-UHFFFAOYSA-N 0.000 description 1
- 229960000588 flunixin Drugs 0.000 description 1
- 229940124307 fluoroquinolone Drugs 0.000 description 1
- MLBZKOGAMRTSKP-UHFFFAOYSA-N fluralaner Chemical compound C1=C(C(=O)NCC(=O)NCC(F)(F)F)C(C)=CC(C=2CC(ON=2)(C=2C=C(Cl)C=C(Cl)C=2)C(F)(F)F)=C1 MLBZKOGAMRTSKP-UHFFFAOYSA-N 0.000 description 1
- 229960004498 fluralaner Drugs 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 201000010231 gastrointestinal system cancer Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229960002706 gusperimus Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- PJBQYZZKGNOKNJ-UHFFFAOYSA-M hydron;5-[(2-methylpyridin-1-ium-1-yl)methyl]-2-propylpyrimidin-4-amine;dichloride Chemical compound Cl.[Cl-].NC1=NC(CCC)=NC=C1C[N+]1=CC=CC=C1C PJBQYZZKGNOKNJ-UHFFFAOYSA-M 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 201000010659 intrinsic asthma Diseases 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- 229960002418 ivermectin Drugs 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 description 1
- 229960000681 leflunomide Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229950008325 levothyroxine Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N linoleic acid group Chemical group C(CCCCCCC\C=C/C\C=C/CCCCC)(=O)O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 229950002303 lotilaner Drugs 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000003120 macrolide antibiotic agent Substances 0.000 description 1
- 229940041033 macrolides Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 238000009115 maintenance therapy Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- TTZNQDOUNXBMJV-UHFFFAOYSA-N mavacoxib Chemical compound C1=CC(S(=O)(=O)N)=CC=C1N1C(C=2C=CC(F)=CC=2)=CC(C(F)(F)F)=N1 TTZNQDOUNXBMJV-UHFFFAOYSA-N 0.000 description 1
- 229950007241 mavacoxib Drugs 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 235000013622 meat product Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229960001929 meloxicam Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- PMRYVIKBURPHAH-UHFFFAOYSA-N methimazole Chemical compound CN1C=CNC1=S PMRYVIKBURPHAH-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- CKVMAPHTVCTEMM-ALPQRHTBSA-N milbemycin oxime Chemical compound O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\2)O)C[C@H]4C1.C1C[C@H](C)[C@@H](CC)O[C@@]21O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)C(=N/O)/[C@H]3OC\1)O)C[C@H]4C2 CKVMAPHTVCTEMM-ALPQRHTBSA-N 0.000 description 1
- 229940099245 milbemycin oxime Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 description 1
- 229960004816 moxidectin Drugs 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940014456 mycophenolate Drugs 0.000 description 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- IDINUJSAMVOPCM-INIZCTEOSA-N n-[(1s)-2-[4-(3-aminopropylamino)butylamino]-1-hydroxy-2-oxoethyl]-7-(diaminomethylideneamino)heptanamide Chemical compound NCCCNCCCCNC(=O)[C@H](O)NC(=O)CCCCCCN=C(N)N IDINUJSAMVOPCM-INIZCTEOSA-N 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- GPLGAQQQNWMVMM-FCGWIEHOSA-N nerine Chemical compound C1C=C2CC(N(C)C)CC[C@]2(C)C2C1C1CCC3C(C)N(C)C[C@@]31CC2 GPLGAQQQNWMVMM-FCGWIEHOSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- HYWYRSMBCFDLJT-UHFFFAOYSA-N nimesulide Chemical compound CS(=O)(=O)NC1=CC=C([N+]([O-])=O)C=C1OC1=CC=CC=C1 HYWYRSMBCFDLJT-UHFFFAOYSA-N 0.000 description 1
- 229960000965 nimesulide Drugs 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 239000008184 oral solid dosage form Substances 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 229960002695 phenobarbital Drugs 0.000 description 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- GLBJJMFZWDBELO-UHFFFAOYSA-N pimobendane Chemical compound C1=CC(OC)=CC=C1C1=NC2=CC=C(C=3C(CC(=O)NN=3)C)C=C2N1 GLBJJMFZWDBELO-UHFFFAOYSA-N 0.000 description 1
- 229960002702 piroxicam Drugs 0.000 description 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 description 1
- 208000030428 polyarticular arthritis Diseases 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 1
- 229960001233 pregabalin Drugs 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 229960003712 propranolol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 229960000996 pyrantel pamoate Drugs 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
- 150000007660 quinolones Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229960003401 ramipril Drugs 0.000 description 1
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000022983 regulation of cell cycle Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- ZEXGDYFACFXQPF-UHFFFAOYSA-N robenacoxib Chemical compound OC(=O)CC1=CC(CC)=CC=C1NC1=C(F)C(F)=CC(F)=C1F ZEXGDYFACFXQPF-UHFFFAOYSA-N 0.000 description 1
- 229960000205 robenacoxib Drugs 0.000 description 1
- 229960005393 sarolaner Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- DGQSERIFTYSYLE-UHFFFAOYSA-M sodium 2-(2-decanoyloxypropanoyloxy)propanoate Chemical compound [Na+].CCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O DGQSERIFTYSYLE-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960002178 thiamazole Drugs 0.000 description 1
- 229940035024 thioglycerol Drugs 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229960004380 tramadol Drugs 0.000 description 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 235000015192 vegetable juice Nutrition 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Abstract
The present invention is directed to a soft chewable composition comprising or containing a therapeutically effective amount of a veterinary active agent, preferably a JAK inhibitor; an animal based palatant, a non-animal based palatant, a flavor modifier, and at least one veterinary acceptable excipient that is selected from at least one each of a disintegrant, binder, lubricant, humectant, and glidant; and wherein the soft chewable tablet is compressed with a rotary tablet press; and methods for treating or preventing cancer, asthma, atopic dermatitis, autoimmune disorders, pruritus associated with allergic dermatitis, allergies, and chronic respiratory disease in an animal.
Description
PALATABLE ATIONS Field of invention This ion describes a stable, palatable soft le composition that comprises at least one veterinary able active ingredient, at least one animal based palatant, at least one non-animal based palatant, and at least one additional veterinary acceptable ent; and methods of use for treating and/or preventing many diseases, including but not limited to cancer, cardiovascular diseases, allergies, asthma and other respiratory diseases, autoimmune diseases, inflammatory diseases, bone diseases, and other metabolic disorders.
The soft chew s are prepared without extrusion and are compressed with a rotary tablet press.
Background of the Invention n kinases are families of enzymes that catalyze the orylation of specific residues in proteins, broadly classified into ne and serine/threonine kinases. Inappropriate kinase activity, arising from mutation, over-expression, or inappropriate regulation, dis-regulation or de-regulation, as well as over- or under-production of growth factors or cytokines has been implicated in many diseases, including but not limited to cancer, allergies, asthma and other respiratory es, autoimmune es, and inflammatory diseases. opriate kinase activity triggers a variety of biological cellular responses relating to cell growth, cell differentiation, survival, apoptosis, nesis, cell cycle control, and cell mobility.
Thus, n kinases have emerged as an important class of enzymes as targets for therapeutic intervention. In particular, the JAK family of cellular protein tyrosine kinases (JAK-1, JAK-2, JAK-3, and Tyk-2) play a central role in cytokine signaling (Kisseleva et al, Gene, 2002, 285, 1; Yamaoka et al. Genome Biology 2004, 5, 253)). Upon binding to their receptors, cytokines activate JAK which then phosphorylate the cytokine receptor, thereby creating docking sites for signaling molecules, notably, members of the signal transducer and activator of transcription (STAT) family that ultimately lead to gene expression. Numerous cytokines are known to activate the JAK family. ation of a drug (i.e., active agent) into an edible medication, such as a palatable, chewable dosage form, can increase subject acceptance of the medication, especially animals that tend to resist wing s or capsules and chewing bitter and/or granular dosage forms. Flavorings and polymeric coatings have commonly been used to provide some degree of palatability to the dosage form. Chewable itions can be ed by granulating the active veterinary ingredient with oils, fats, waxes, and water to prepare a dough-like composition for extrusion processes. These compositions, however, tend to be oily and gummy. Other chewable compositions can be prepared in a similar manner, but the dough is rolled into a sheet of different thicknesses and then punch-cut into appropriate sizes. The present invention achieves a palatable soft chew composition that can be compressed into tablets via rotary compression.
Soft chews have been described previously. However, the prior palatable tablets have been prepared using non-animal based palatants (WO2004/016252), use of partially pre-gelatinized starch (WO2005/013714); formulations with 5-30% weight of fats, waxes, and oils (WO2014/033230) which tend to impart a "greasy" feel to the tablet; blending API (with or without oil) with dry excipients under low-shear conditions and wherein each process step is conducted without the introduction of heat (WO2007/067582) for heat labile actives; formation of dough like compositions for compression with a rotary molding machine (WO2014/079825); use of sugar (5-75%) as a sweet filler (WO2004/014143); and manufacture of a soft (<2kp) tablet sing 5-20% oil and 5-20% ol (WO2017/106812). The ition of the ion does not incorporate fats, oils, pre-gelatinized starches, s), and the like; but rather prepares a common blended and milled ate that can be easily compressed into tablets using a rotary tablet press.
In this specification where reference has been made to patent specifications, other external documents, or other sources of information, this is lly for the purpose of providing a context for discussing the features of the invention. Unless specifically stated otherwise, reference to such external documents is not to be construed as an admission that such documents, or such s of information, in any iction, are prior art, or form part of the common general knowledge in the art.
Summary of the Invention In accordance with this ion, it has been discovered that the oral compositions of the invention are stable, ble, safe, and efficacious.
Increased stability correlates with increased shelf-life, and optimally, efficacy, while palatability increases patient compliance. In addition, the granulation can be compressed with a rotary tablet press.
In one aspect, the invention describes soft chew veterinary compositions comprising or containing a veterinary active ingredient; at least one animal based palatant, at least one non-animal based palatant; and at least one veterinary acceptable excipient. In another aspect, the at least one veterinary able excipient includes at least one of each of a disintegrant, binder, humectant, glidant, and lubricant; and wherein the composition is compressed with a rotary tablet press.
In a particular aspect, the present invention provides a palatable soft chewable tablet veterinary composition comprising: a. a therapeutically effective amount of a veterinary active agent, wherein the veterinary active agent is oclacitinib or a veterinary acceptable salt thereof; b. at least one animal based palatant in an amount of about 45w/w% to about 55w/w% of the total weight of the tablet; c. at least one non-animal based palatant in an amount of about 10w/w% to about 15w/w% of the total weight of the ; d. at least one veterinary acceptable excipient; and n the soft-chewable tablet is compressed with a rotary tablet press.
In another particular , the present ion provides a palatable soft chewable tablet veterinary composition comprising: a. a therapeutically effective amount of oclacitinib maleate that is in an amount of about 4w/w% to about 5w/w% of the total weight of the tablet; b. an animal based palatant that is derived from pork liver; [FOLLOWED BY PAGE 3a] c. a non-animal based palatant that is Brewer’s yeast; d. a mixture of veterinary acceptable excipients, that is one each of a disintegrant, binder, humectant, lubricant, glidant, and flavor modifier; and wherein the soft chewable tablet is compressed with a rotary tablet press.
In a r particular aspect, the present invention provides a palatable soft chewable tablet veterinary ition comprising: a. a therapeutically effective amount of oclacitinib maleate in an amount of about 4w/w% of the total weight of the tablet; b. a mixture of palatants in an amount of about 55w/w% to about 70w/w% of the total weight of the tablet comprising an animal based palatant and a mal based palatant; c. a mixture of binders in an amount of about 5w/w% to about 7w/w% of the total weight of the tablet selected from polyethylene glycol 3350 and n d. a mixture of disintegrants in an amount of about 8w/w% to about 18w/w% of the total weight of the tablet comprising crospovidone and sodium starch glycolate; e. the humectant glycerol in an amount of about 11w/w% to about 14w/w% of the total weight of the tablet; f. a flavor modifier that is sodium chloride in an amount of about 0.4w/w% to about 0.6w/w% of the total weight of the tablet; g. a glidant that is colloidal silicon dioxide in an amount of about 1w/w% to about 3w/w% of the total weight of the table; and wherein the soft chewable tablet is compressed on a rotary tablet press.
In one aspect, the invention describes soft chew veterinary compositions comprising or ning a veterinary active ingredient, wherein said active ingredient is a JAK tor, at least one animal based palatant, at least one non-animal based palatant, and at least one veterinary acceptable excipient comprising at least one of each of a disintegrant, binder, humectant, t, and lubricant; and wherein the composition is compressed with a rotary tablet press.
In one , the invention describes soft chew veterinary compositions comprising or containing a nary active ingredient, whererin said active ingredient is the JAK inhibitor, oclacitinib, N-methyl{trans thyl(7 H- [FOLLOWED BY PAGE 3b] pyrrolo[2,3-d]pyrimidinyl)amino]cyclohexyl}-methanesulfonamide, or a veterinary acceptable salt thereof; at least one animal based palatant, at least one non-animal based palatant, and at least one veterinary acceptable excipient.
In r aspect, the active ingredient is tinib maleate (Apoquel®; N- methyl{trans [methyl(7 H-pyrrolo[2,3-d]pyrimidinyl)amino]cyclohexyl}- methanesulfonamide (2Z)butenedioate te)) and the composition comprises at least one animal based palatant, at least one non-animal based palatant, and at least one veterinary acceptable excipient selected from at least one of each of a disintegrant, binder, humectant, glidant, and lubricant. In one aspect, the amount of oclacitinib maleate is in the amount of about 4w/w% to 5w/w% of the total weight of the tablet. In one aspect, the amount of oclacitinib e is in the amount of about 4w/w% /w%) of the total weight of the tablet.
In another aspect of the invention, the composition comprises or contains at least two palatants in the amount of about 55w/w% to about 70w/w%, including one animal based palatant and one non-animal based palatant. In [FOLLOWED BY PAGE 4] another aspect of the invention, the animal based palatant is in the amount of about 45w/w% to about 55w/w% of the total tablet weight. In another aspect, the animal based palatant is in the amount of about 46w/w% to about 52w/w% of the total weight of the . The preferred amount of the animal-based palatant is about 48w/w% to about 50w/w% of the total weight of the tablet. The preferred animal based palatant is derived from swine (pig). The more preferred animal based palatant is derived from pig liver. The most preferred animal based palatant is pork liver powder. In another aspect of the invention, the non-animal based palatant is in the amount of about 10w/w% to about 15w/w% of the total weight of the tablet. In another aspect, the preferred amount of the non-animal based palatant is in the amount of about 11w/w% to about 14w/w% of the total weight of the tablet. The preferred non-animal based palatant is yeast. The preferred yeast is Brewer’s yeast. In another aspect of the invention, the composition comprises about 46w/w% to about 52w/w% of an animal based palatant and about 11w/w% to about 14w/w% of a non-animal based palatant, both accounting for the w/w% of the total weight of the tablet.
In r aspect of the invention, the composition comprises or contains about 0.4w/w% to about 0.6w/w% of the total weight of the tablet of a flavor modifier. The preferred flavor modifier is sodium chloride or ium chloride.
The preferred flavor modifier is sodium de.
In another aspect of the invention, the composition further comprises or ns at least one veterinary acceptable excipient ed from at least one each of a disintegrant, , humectant, lubricant, and t.
In one aspect of the invention, the at least one disintegrant is in the amount of about 8w/w% to about 18w/w% of the total weight of the tablet. In yet another aspect, the at least one disintegrant is in the amount of about 10w/w% to about 15w/w% of the total weight of the tablet. In one , the egrant is selected from the group consisting of crospovidone, sodium starch glycolate, or mixture thereof. In another aspect, the disintegrant is a e of magnesium stearate and glyceryl monostearate.
In yet another aspect of the invention, the at least one binder is in the amount of about 5w/w% to about 7w/w% of the total weight of the tablet. In another aspect, the binder is in the amount of about 5w/w% to about 6.5w/w% of the total weight of the tablet. In one aspect, the at least one binder is selected from the group ting of polyethylene , a gum, or mixture thereof. The preferred polyethylene glycol is polyethylene glycol 3350; and the preferred gum is n gum. In one , the composition comprises or contains a mixture of polyethylene glycol 3350 and xanthan gum. In one aspect, the amount of polyethylene glycol 3350 is in the amount of about 5w/w% to about 6w/w% of the total weight of the tablet.
In another aspect of the invention, the at least one humectant is in the amount of about 10w/w% to about 15w/w% of the total weight of the tablet. In another aspect, the humectant is in the amount of about 11w/w% to about 14w/w% of the total weight of the tablet. In one aspect, the humectant is glycerol.
In another aspect of the invention, the at least one lubricant is about 1w/w% to about 2w/w% of the total weight of the tablet. In another aspect, the lubricant is selected from the group consisting of magnesium stearate, glycerol monostearate, or mixture thereof. In another aspect, the lubricant is a mixture of magnesium te and glyceryl monostearate.
In another aspect of the invention, the at least one glidant is in the amount of about 1w/w% to about 3w/w% of the total weight of the . The preferred amount of glidant is about 1,5w/w% to about 2.5w/w% of the total weight of the tablet. In one aspect, the glidant is colloidal silicon dioxide.
In yet another aspect of the invention, is a palatable soft chewable tablet veterinary composition comprising or containing a therapeutically ive amount of oclacitinib maleate in the amount of about 4w/w% to about 5w/w%; an animal based palatant in the amount of about 46w/w% to about ; a nonanimal based nt in the amount of about 11w/w% to about 14w/w%; a flavor modifier in the amount of about % to about 0.6w/w%; at least one disintegrant in the amount of about 10w/w% to about 15w/w%; at least one binder in the amount of about 5w/w% to about 7w/w%; at least one humectant in the amount of 11w/w% to about 14w/w%, at least one glidant in the amount of about 1w/w% to about 3w/w%, and at least one lubricant in the amount of about 1w/w% to about 2w/w%; and wherein each of the w/w% are based on the total weight of the tablet. In yet another aspect of the invention, is a palatable soft chewable tablet veterinary composition containing a therapeutically effective amount of oclacitinib maleate in the amount of about 4w/w% to about 5w/w%; an animal based palatant in the amount of about 46w/w% to about 52w/w%; a nonanimal based palatant in the amount of about 11w/w% to about 14w/w%; a flavor modifier in the amount of about 0.4w/w% to about 0.6w/w%; at least one disintegrant in the amount of about 10w/w% to about 15w/w%; at least one binder in the amount of about 5w/w% to about 7w/w%; at least one humectant in the amount of 11w/w% to about , at least one glidant in the amount of about 1w/w% to about 3w/w%, and at least one lubricant in the amount of about 1w/w% to about 2w/w%; and n each of the w/w% are based on the total weight of the tablet; and wherein the tablet is ssed with a rotary tablet press.
In yet another aspect of the invention, is a palatable soft chewable tablet veterinary composition comprising or containing a therapeutically effective amount of oclacitinib maleate in the amount of about 4w/w% to about 5w/w%; an animal based palatant that is pork liver powder in the amount of about 46w/w% to about 52w/w%; a non-animal based palatant that is Brewer’s yeast in the amount of about 11w/w% to about 14w/w%; a flavor modifier that is sodium chloride in the amount of about 0.4w/w% to about 0.6w/w%; at least one disintegrant that is a mixture of crospovidone and sodium starch glycolate in the amount of about 10w/w% to about 15w/w%; at least one binder that is a mixture of polyethylene glycol 3350 and xanthan gum in the amount of about 5w/w% to about 7w/w%; a humectant that is ol in the amount of about 11w/w% to about 14w/w%; a glidant that is colloidal silicon dioxide in the amount of about 1w/w% to about 3w/w%; and at least one lubricant that is a mixture of glycerol earate and magnesium stearate in the amount of about 1w/w% to about 2w/w%; and wherein each of the w/w% are based on the total weight of the tablet. In yet another aspect of the invention, is a ble soft chewable tablet veterinary composition containing a therapeutically ive amount of oclacitinib maleate in the amount of about 4w/w% to about 5w/w%; an animal based palatant that is pork liver powder in the amount of about 46w/w% to about ; a non-animal based palatant that is Brewer’s yeast in the amount of about 11w/w% to about 14w/w%; a flavor modifier that is sodium chloride in the amount of about 0.4w/w% to about 0.6w/w%; at least one disintegrant that is a mixture of crospovidone and sodium starch ate in the amount of about 10w/w% to about 15w/w%; at least one binder that is a mixture of polyethylene glycol 3350 and xanthan gum in the amount of about 5w/w% to about 7w/w%; a humectant that is glycerol in the amount of about 11w/w% to about 14w/w%; a glidant that is colloidal silicon dioxide in the amount of about 1w/w% to about 3w/w%; and at least one lubricant that is a mixture of glycerol monostearate and magnesium stearate in the amount of about 1w/w% to about 2w/w%; and n each of the w/w% are based on the total weight of the tablet; and wherein the tablet is compressed with a rotary tablet press.
In yet another aspect of the invention, is a palatable soft chewable tablet veterinary composition comprising or containing a therapeutically effective amount of oclacitinib maleate in the amount of about 4w/w% to about 5w/w%; an animal based palatant that is pork liver powder in the amount of about 48w/w% to about 50w/w%; a non-animal based palatant that is Brewer’s yeast in the amount of about 11w/w% to about 14w/w%; a flavor modifier that is sodium chloride in the amount of about 0.4w/w% to about %; at least one disintegrant that is a mixture of crospovidone and sodium starch ate in the amount of about 10w/w% to about 15w/w%; at least one binder that is a mixture of polyethylene glycol 3350 and xanthan gum in the amount of about 5w/w% to about 7w/w%; a humectant that is glycerol in the amount of about 11w/w% to about 14w/w%; a glidant that is colloidal silicon dioxide in the amount of about 1,5w/w% to about 2.5w/w%; and at least one lubricant that is a mixture of glycerol monostearate and ium stearate in the amount of about 1w/w% to about 2w/w%; and wherein each of the w/w% are based on the total weight of the tablet. In yet another aspect of the invention, is a palatable soft chewable tablet veterinary composition containing a therapeutically effective amount of oclacitinib maleate in the amount of about 4w/w% to about 5w/w%; an animal based palatant that is pork liver powder in the amount of about 48w/w% to about 50w/w%; a non-animal based palatant that is ’s yeast in the amount of about 11w/w% to about 14w/w%; a flavor er that is sodium chloride in the amount of about 0.4w/w% to about 0.6w/w%; at least one egrant that is a mixture of crospovidone and sodium starch glycolate in the amount of about 10w/w% to about 15w/w%; at least one binder that is a mixture of polyethylene glycol 3350 and xanthan gum in the amount of about 5w/w% to about 7w/w%; a humectant that is glycerol in the amount of about 11w/w% to about 14w/w%; a glidant that is colloidal silicon dioxide in the amount of about 1.5w/w% to about 2.5w/w%; and at least one lubricant that is a mixture of glycerol monostearate and magnesium stearate in the amount of about 1w/w% to about 2w/w%; and wherein each of the w/w% are based on the total weight of the tablet; and wherein the tablet is compressed with a rotary tablet press.
In yet another aspect of the invention, is a method of treatment of or prevention of cancer, asthma, atopic dermatitis, autoimmune disorders, pruritus associated with allergic dermatitis, allergies, and chronic atory disease in a companion animal; by orally stering the soft chewable tablet composition sing or containing a therapeutically effective amount of oclacitinib maleate in the amount of about 4w/w% to about 5w/w%; an animal based palatant in the amount of about 46w/w% to about 52w/w%; a non-animal based palatant in the amount of about 11w/w% to about 14w/w%; a flavor modifier in the amount of about 0.4w/w% to about 0.6w/w%; at least one disintegrant in the amount of about 10w/w% to about 15w/w%; at least one binder in the amount of about 5w/w% to about 7w/w%; a humectant in the amount of about 11w/w% to about 14w/w%; a glidant in the amount of about 1w/w% to about 3w/w%; and at least one lubricant in the amount of about 1w/w% to about 2w/w%; and wherein each of the w/w% are based on the total weight of the tablet; and n the tablet is ssed with a rotary tablet press.
Preferably, the composition is for the treatment and prevention of atopic dermatitis, pruritus associated with allergic dermatitis and allergies in a ion . Preferably, the companion animal is a dog or horse.
In yet another aspect of the invention, is a use of the soft chewable tablet composition sing or containing a therapeutically effective amount of oclacitinib maleate in the amount of about 4w/w% to about 5w/w%; an animal based palatant in the amount of about 46w/w% to about 52w/w%; a non-animal based nt in the amount of about 11w/w% to about 14w/w%; a flavor modifier in the amount of about 0.4w/w% to about 0.6w/w%; at least one disintegrant in the amount of about 10w/w% to about 15w/w%; at least one binder in the amount of about 5w/w% to about 7w/w%; a humectant in the amount of about 11w/w% to about 14w/w%; a glidant in the amount of about 1w/w% to about 3w/w%; at least one lubricant in the amount of about 1w/w% to about 2w/w%; and n each of the w/w% are based on the total weight of the tablet; and wherein the tablet is compressed with a rotary tablet press; for the treatment of or prevention of cancer, asthma, atopic dermatitis, autoimmune disorders, pruritus associated with allergic dermatitis, allergies, and chronic respiratory disease in a companion ; by orally administering the soft le tablet composition to the companion animal in need thereof.
Preferably, the use is for the treatment and prevention of atopic dermatitis, pruritus associated with ic dermatitis and allergies in a companion animal.
The preferred companion animal is a dog or horse.
In yet another aspect of the invention, is the use of the soft chewable composition comprising or containing a therapeutically effective amount of oclacitinib maleate in the amount of about 4w/w% to about 5w/w%; an animal based palatant in the amount of about 46w/w% to about 52w/w%; a non-animal based palatant in the amount of about 11 w/w% to about 14w/w%; a flavor modifier in the amount of about 0.4w/w% to about 0.6w/w%; at least one disintegrant in the amount of about 10w/w% to about ; at least one binder in the amount of about 5w/w% to about 7w/w%; a humectant in the amount of about 11w/w% to about 14w/w%; a glidant in the amount of about 1w/w% to about 3w/w%; at least one lubricant in the amount of about 1w/w% to about 2w/w%; and wherein each of the w/w% are based on the total weight of the tablet; and wherein the tablet is ssed with a rotary tablet press; for preparing a ment for the treatment of or prevention of cancer, asthma, atopic dermatitis, autoimmune disorders, pruritus associated with ic dermatitis, allergies, and chronic respiratory disease in a companion animal.
Preferably, for treatment and prevention of atopic dermatitis, pruritus associated with allergic itis and allergies in a companion animal. The preferred companion animal is a dog or horse.
In yet another aspect of the ion, is a soft le composition comprising or containing an animal based palatant in the amount of about 45w/w% to about 55w/w%; a non-animal based palatant in the amount of about 10w/w% to about 15w/w%; a flavor modifier in the amount of about % to about 0.6w/w%; at least one disintegrant in the amount of about 8w/w% to about 18w/w%; at least one binder in the amount of about 5w/w% to about 7w/w%; a humectant in the amount of about 10w/w% to about 15w/w%; a glidant in the amount of about 1w/w% to about 3w/w%; at least one lubricant in the amount of about 1w/w% to about 2w/w%; and wherein each of the w/w% are based on the total weight of the tablet; for preparing a soft treat for a companion animal; and wherein said treat is compressed with a rotary tablet press.
In the description in this specification reference may be made to subject matter which is not within the scope of the appended claims. That subject matter should be readily fiable by a person d in the art and may assist in putting into practice the invention as defined in the ed claims.
Definitions For purposes of the present invention, as described and claimed herein, the following terms and phrases are d as follows: Unless the context clearly requires otherwise, throughout the description and the claims, the words ‘comprise’, ‘comprising’ and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is to say in the sense of "including but not limited to".
"Animal", as used herein, unless ise indicated, refers to a vertebrate animal that is non-human, which are members of the taxonomic class Animalia.
Non-exclusive es of animal include companion animals and livestock.
Non-exclusive es of a companion animal include: dog (canine), cat (feline), and horse (equine). Preferred companion animals are dog and cat. More preferred is dog. Non-exclusive examples of livestock include: pig, goat, sheep, and cattle. The term also refers to other animals, for example, deer, ferret, guinea pig, rabbit, zoo s (e.g., bear, large cats, camel, kangaroo, and the like).
"At least one", as used herein, unless otherwise indicated, refers to one or more agents, e.g ., at least one nary acceptable excipient means one excipient; it also refers to 2 excipients, 3 excipients, 4 excipients, and the like.
"Composition of the invention", or "composition" as used herein, unless otherwise indicated, refers to a stable, ble, soft chewable composition ed for oral administration to an animal, preferably a canine animal, a feline animal, or an equine animal.
"Therapeutically effective amount", as used herein, unless otherwise indicated, refers to an amount of an active agent or ation of active agents that treats, prevents, attenuates, ameliorates, delays, or eliminates one or more [FOLLOWED BY PAGE 10a] symptoms in the animal being treated.
"Treatment", "treating", and the like, as used herein, unless otherwise indicated, refers to reversing, alleviating, or inhibiting, for e, pruritis, asthma, allergic dermatitis, and the like. As used herein, these terms also encompass, depending on the condition of the animal, preventing the onset of a disorder or ion, or of symptoms associated with a disorder or condition, ing reducing the severity of a er or condition or symptoms associated therewith prior to affliction of said condition. Thus, treatment can refer to administration of the composition with at least one veterinary agent to the animal [FOLLOWED BY PAGE 11] that is not at the time of administration ted with said condition. Treating also encompasses preventing the recurrence of symptoms associated therewith.
"Veterinary acceptable" as used herein, unless otherwise indicated, indicates that the substance or composition is compatible ally and/or toxicologically, with the other ingredients comprising a formulation, composition, and/or the animal being treated therewith.
As used herein, percent of components of the composition refers to percentages of the total weight of the chewable tablet and is referred to as "%w/w" or "w/w%" which defines the mass on of the itional component expressed as a percentage, determined according to the formula mi/ mtot x 100, wherein mi is the mass of the substance of interest present in the composition, and mtot is the total mass of the composition. The w/w% also define the amount of an active ingredient or other compositional component in a granulation mixture, e.g., amount of palatant in the chewable granulation.
Detailed Description The present invention es a stable, palatable, soft chewable composition for oral administration of a therapeutically effective amount of a veterinary acceptable active agent, and wherein said chewable tablet is compressed on a rotary compression tablet press.
A tablet press is a mechanical device that compresses powder (i.e., granulations and or ) into tablets of m size and weight. To form a , the granulated material must be metered into a cavity formed by two punches and a die, and then the punches must be pressed together with great force to fuse the material together. A tablet is formed by the combined pressing action of two punches and a die. In the first step of a l operation, the bottom punch is lowered in the die ng a cavity into which the granulated feedstock is fed. The exact depth of the lower punch can be precisely lled to meter the amount of powder that fills the cavity. The excess is scraped from the top of the die, and the lower punch is drawn down and temporarily covered to prevent spillage. Then, the upper punch is brought down into contact with the powder as the cover is removed. The force of compression is delivered by high pressure compression rolls which fuse the granulated material er into a hardened tablet. After compression, the lower punch is raised to eject the tablet.
There are 2 types of tablet presses: single-punch and rotary tablet presses. Most peed tablet presses take the form of a rotating turret that holds any number of punches. As they rotate around the turret, the s come into contact with cams which control the punch's vertical position. Punches and dies are usually custom made for each application, and can be made in a wide variety of sizes, shapes, and can be customized with manufacturer codes and scoring lines. Depending on tablet size, shape, material, and press configuration, a typical modern press can produce from 250,000 to over 1,000,000 tablets an hour. Common manufacturers of tablet presses include Natoli, Stokes, Fette ting, Korsch, Kikusui, Manesty, B&D, PTK, IMA and Courtoy.
Soft chewable tablets have typically been manufactured by blending and extrusion, blending and out, and use of injection molds, using waxy, oily, doughs. For extrusion, pre-mixed ingredients are introduced into an extruder barrel with a single ortwin screw therein, then mixed, coagulated, expanded and sheared into a blended mixture, followed by application of additional heat or water for proper extrusion. The d and extruded mixture is then formed into a desired shape on a die plate and cut into individual units. Texture, shape and weights of the chews from batch to batch of extruded material can be inconsistent and tend to lack efficiency.
Rotary molding machines (e.g., Formax F6™by the Formax Corporation) work by displacing dough between a rotary mold roller and removal from the mold without a punch mechanism. ion g consists of high pressure, and ially high temperature, injection of the raw material into a mold which shapes the material into any desired shape. It is most typically used in massproduction processes where the same part is being created thousands or even millions of times in succession. Molds can be of a single cavity or multiple cavities. In multiple cavity molds, each cavity can be identical and form the same parts or can be unique and form multiple different geometries during a single cycle. Generally, the final product must be displaced from the mold. The use of extruders, g machines and rotary molding machines exhibit ms associated with the weight and physical forms of a final dosage form. Moreover, the use of such logies may require conditioning of the final dosage form (e.g. drying or curing final formed structure) for consolidation of shape and structure of formed structure. Use of such technologies, equipment and processes is complex, cumbersome, and ing that is not traditionally used in a typical pharmaceutical oral solid dosage form cturing set-up.
As described herein, the stable, palatable, soft chew tablet is ssed with a standard rotary tablet compression machine.
According to the invention, a preferred veterinary acceptable active agent is oclacitinib, or a veterinary acceptable salt thereof. Oclacitinib is the compound of Formula 1, N \ (maleate) N co2h N H and has the chemical name: N-methyl{trans[methyl(7H-pyrrolo[2,3- midinyl)amino]cyclohexyl}methanesulfonamide. The compound of Formula (1) and it’s commercial salt, e, is referred to herein as Apoquel®; depicted above.
Additional veterinary acceptable salts of oclacitinib include, but are not limited to: acetate, ascorbate, aspartate, te, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, edisylate, etoglutarate, esylate, formate, fumarate, tate, gluconate, glucuronate, glycerophosphate, uorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, odide/iodide, isethionate, e, malate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, saccharate, stearate, succinate, tartrate, tosylate and oroacetate salts.
Apoquel is a Janus Kinase inhibitor (JAK-i) with efficacy against Janus Kinase-1 (JAK-1), Janus Kinase-2 (JAK-2) and Janus Kinase-3 (JAK-3), and particularly, JAK-1. Accordingly, it is useful as a therapeutic agent for cancer, asthma, atopic dermatitis, autoimmune disorders, control of pruritus, allergies, chronic respiratory disease and other indications where immunosuppression and/or immunomodulation would be desirable. A preferred use is for the l of us associated with allergic dermatitis and control of atopic dermatitis in companion animals, particularly dogs.
Accordingly, the nd of Formula 1 or its veterinary acceptable salts and veterinary compositions can be used to treat a variety of conditions or diseases such as: - asthma and other obstructive airways es, including chronic or inveterate asthma, late asthma, airway hyper-responsiveness, bronchitis, bronchial asthma, allergic asthma, intrinsic asthma, extrinsic asthma, dust asthma, recurrent airway obstruction, and chronic obstruction pulmonary disease; -autoimmune diseases or disorders, including those designated as single organ or single cell-type autoimmune disorders, for example autoimmune hemolytic anemia, autoimmune atrophic tis of ious anemia, autoimmune encephalomyelitis, autoimmune orchitis, mune thrombocytopenia, sympathetic ophthalmia, ulcerative s and membranous glomerulopathy, those ated as ing systemic autoimmune disorder, for example systemic lupus erythematosis, systemic sclerosis, and bullous pemphigoid, osteoarthritis (i.e., degenerative joint disease), non-erosive immune-mediated polyarthritis, traumatic arthritis, and additional autoimmune diseases, which can be O-cell (humoral) based orT-cell based, including autoimmune alopecia and thyroiditis; -cancers or tumors, ing alimentary/gastrointestinal tract cancer, colon cancer, liver cancer, skin cancer including mast cell tumor and squamous cell oma, breast and mammary cancer, ovarian cancer, prostate , lymphoma, leukemia, including acute myelogenous leukemia and chronic myelogenous leukemia, kidney cancer, lung cancer, muscle cancer, bone cancer, bladder cancer, brain cancer, melanoma including oral and metastatic ma, Kaposi's sarcoma, myelomas including multiple a, myeloproliferative disorders, proliferative ic retinopathy, and angiogenicassociated disorders including solid tumors; -eye es, disorders or conditions including mune diseases of the eye, keratoconjunctivitis and keratoconjunctivitis sicca (dry eye); -intestinal inflammations, ies or conditions including ulcerative colitis, inflammatory bowel disease, coeliac diseases, proctitis, eosinophilic gastroenteritis, and mastocytosis; -skin diseases, conditions or disorders including atopic itis, eczema, psoriasis, scleroderma, pruritus and other pruritic conditions; -allergic ons including allergic dermatitis in an animal including horse allergic diseases such as bite hypersensitivity, summer eczema and sweet itch.
The Formula 1 compound may be stered in a veterinary able form (e.g., soft chew tablet) either alone or in combination with one or more additional agents that modulate an animal’s immune system or with antiinflammatory agents. These agents may include but are not limited to cyclosporin A, rapamycin, FK-506 (tacrolimus), leflunomide, deoxyspergualin, mycophenolate, azathioprine, daclizumab, aspirin, acetaminophen, ibuprofen, naproxen, piroxicam, and anti-inflammatory steroids (e.g. prednisolone or dexamethasone). These agents may be administered as part of the same or separate dosage forms, via the same or different routes of administration, and on the same or different administration schedules ing to standard veterinary practice known to one skilled in the art.
According to the invention, other veterinary active JAK inhibitor agents that can be ated into the palatable soft chew composition besides Apoquel®, include: 3-(3-((2-methyl-7FI-pyrrolo[2,3-d]pyrimidin no)piperidin-1 -yl)oxopropanenitrile and 1 -((3R,4S)cyanotetrahydro- 2FI-pyranyl)((2-fluoromethoxypyridinyl)amino)-1 FI-pyrazole amide. In addition to the JAK inhibitor agents, the following non-limiting veterinary active agents can be formulated with the palatable soft chew composition of the ion, and include: antimicrobials/antibacterials (e.g., quinolones, fluoroquinolones, cephalosporins (1st, 2nd, 3rd, and 4th generation), yclines, penicillins, I3>-Iactams, macrolides, phenicols, pyrantel pamoate (embonate), carbapenems, and the like); antiparasitics including isoxazole analogs (e.g., (S)(5'-(5-(3,5-dichlorofluorophenyl)(trifluoromethyl)-4,5- dihydroisoxazolyl)-3'FI-spiro[azetidine-3,1 '-isobenzofuran]-1 -yl) (methylsulfonyl)ethan-l-one (sarolaner); 4-(5-(3-chloro (trifluoromethyl)phenyl)(trifluoromethyl)-4,5-dihydroisoxazolyl)-N-(2-oxo 2-trifluoroethyl)amino)ethyl)-1 -naphthamide (afoxolaner); 4-(5-(3,5- dichlorophenyl)(trifluoromethyl)-4,5-dihydroisoxazolyl)methyl-N-(2-oxo 2-trifluoroethyl)amino)ethyl)-benzamide (fluralaner); and 3-methyl-N-{2-oxo- 2-[(2,2,2-trifluoroethyl)amino]ethyl}[(5S)(3,4,5-trichlorophenyl) (trifluoromethyl)-4,5-dihydro-1,2-oxazolyl]thiophenecarboxamide (lotilaner)); macrocyclic lactones and ycins (e.g., doramectin, ephnomectin, ivermectin, moxidectin, milbemycin oxime, and the like); antiprotozoals (e.g., metronidazole, doxycycline, amprolium, atovaquone, benznidazole, and the like); anti-fungals (e.g., ketoconazole, fluconazole, and the like); inotropes (e.g., pimobendane); neurologic agents (e.g., gabapentin, pregabalin, diazepam, phenobarbital, and the like); cardiovascular agents (e.g., ACE-inhibitors (e.g., benazepril, lisinopril, accupril, ramipril, and the like), betablockers (e.g., nadalol, olol, ol, propranolol, and the like), and 5HT2B inhibitors); NSAIDs and other analgesics (carprofen, ketoprofen, deracoxib, flunixin, nimesulide, firocoxib, mavacoxib, robenacoxib, meloxicam, tramadol, amantadine, dexamethasone, and the like); thyroid agents (e.g., levothyroxine, methimazole, and the like); steroids (e.g., prednisone, prednisolone, thasone, and the like); and behavior-modifying agents and sedatives (e.g., am, xylazine, alprazolam, acepromazine, detomidine, amitriptyline, clomipramine, midazolam, and the like).
In a preferred aspect of the invention, the composition comprises or contains the active veterinary agent: oclacitinib maleate (Apoquel®) in an amount of about 4w/w% to about 5w/w% of the total weight of the tablet. The preferred amount of the active agent, oclacitinib maleate is about 4w/w% (e.g., 4.03w/w%).
The composition of the invention ses or contains at least one animal based palatant and one non-animal based palatant. The palatants are in an amount of about 55w/w% to about 70w/w% of the total tablet weight.
Palatants are used to alter or enhance the flavor(s) of natural food products such as meats and vegetables, or ng additional flavor for food products that do not have the desired s such as snacks and oral medications. Most types of palatants are focused on scent and taste. cial palatants are chemically synthesized compounds that are used to flavor food items and are often formulated with the same chemical nds found in natural palatants. Most artificial s are specific and often complex mixtures of singular naturally occurring flavor compounds to either imitate or enhance a natural flavor. These mixtures are formulated by flavorists to give a food product a unique flavor and to maintain flavor consistency between different product batches or after recipe changes. The list of known flavoring agents includes thousands of molecular compounds, and can be combined to achieve flavors like chicken, turkey, beef, pork, lamb, fish, egg, cheese, seafood, smoke, and many others. A natural palatant is defined as the essential oil, oleoresin, essence or t, n hydrolysate, distillate, or any product of roasting, heating or enzymolysis, which contains the flavoring constituents derived from a spice, fruit or fruit juice, ble or vegetable juice, edible yeast (active and inactive), herb, bark, bud, root, leaf or any other edible portions of a plant, meat, seafood, poultry, eggs, dairy ts, or fermentation products thereof; and can include sweeteners like sucrose; whose primary function in food is flavoring rather than nutritional.
Natural palatants include n, , beef, pork, lamb, fish, egg, cheese, seafood, vegetable and vegetable matter, yeast (e.g., ’s yeast) and mixtures thereof. Yeast extracts are also included in the natural flavors. Flavor (taste) ers, for example sodium chloride, potassium chloride, are also construed herein as a palatant. Natural meat palatants can be obtained from meat, meat products, organ meat, yeast extracts, vegetable matter, and mixtures thereof. For example, an oral veterinary composition tion might include animal product-based flavorings such as dried or powdered meat and meat parts such as beef, pork, chicken, , fish, and lamb; organ meats such as liver and kidney; meat meals, bone meals and ground bone; and animal-derived food such as casein, milk (which may include dry forms and d fat forms, such as dry skim milk), yogurt, gelatin, cheese and egg (collectively, "animal origin flavorings") may be utilized. The natural products may or may not be sterilized by heat or other types of radiation, e.g., gamma-radiation. The preferred palatant for the stable, palatable, chewable composition is a natural animal based palatant. The composition of the invention ses or contains at least two palatants in the amount of about 55w/w% to about 70w/w% of the total weight of the chewable tablet. The composition comprises or contains at least one animal based palatant in the amount of about 45w/w% to about 55w/w% of the total weight of the tablet. The preferred animal based palatant is in the amount of about 46w/w% to about 52w/w% of the total weight of the tablet. The preferred animal based palatant is in the amount of about 48w/w% to 50w/w% of the total weight of the tablet. The red animal based palatant is derived from organ meat. The preferred organ meat is derived from pork liver. The preferred animal based nt is pork liver powder. The composition comprises or contains about 10w/w% to about 15w/w% of the total weight of the tablet of a non-animal based palatant; and preferably about 11w/w/% to about 14w/w% of the total weight of the tablet. ably, the non-animal based palatant is yeast. The preferred yeast is Brewer’s yeast. The composition also comprises or contains about 0.4w/w% to about 0.6w/w% of the total weight of the tablet of a flavor modifier. The preferred flavor er is sodium chloride.
The composition comprises or contains about 48w/w% to about 50w/w% of the total weight of the tablet of an animal based palatant; about 11w/w% to about 14w/w% of a non-animal based palatant, and wherein the w/w% are based on the total weight of the tablet.
The stable, palatable chewable composition comprises or contains at least one veterinary acceptable excipient. The veterinary able excipient includes excipients that are construed as binders, disintegrants, lubricants, glidants, humectants, antioxidants, and colorants. The soft chew tablet comprises or contains the active agent, oclacitinib maleate, an animal based palatant, a non-animal based palatant, a flavor modifier, and at least one each of a binder, disintegrant, humectant, lubricant, and glidant; and is compressed using a rotary tablet press.
Binders are used to add cohesiveness to the composition, thereby providing the necessary bonding to form a cohesive mass and to ensure a suitable ted tablet form. These binding agents are tionally used in direct compression tablets and are described in Lieberman et.al., nary Dosage Forms, 2 Ed., Vol. 1, (1990). miting examples of veterinary acceptable binders e, but are not limited to: rystalline cellulose, carboxymethyl ose, sodium carboxy methyl cellulose, hydroxypropyl cellulose, polyvinylpyrrolidone (e.g., povidone (Kollidon 25, 30, and 90) and copovidone (Kollidon VA 64), polyethylene glycol (PEG), acacia, corn syrup solids, tragacanth gum, xanthan gum, gelatin, ba wax, alginate, and mixtures thereof. Polyethylene glycol (PEG) is a polyether compound with many applications, from rial manufacturing to ne. PEG is also known as polyethylene oxide (PEG) or polyoxyethylene (POE), depending on its molecular weight. The ure of PEG is commonly expressed as H(OCH2CH2)nOH, where n is an integer >3. PEG’S are prepared by rization of ethylene oxide and are commercially ble over a wide range of molecular weights from 300 g/mol to 10,000,000 g/mol. PEG’S are commercially available. A PEG with an n of 9 has an average weight of about 400 daltons (g/mole) and is conveniently labeled as PEG 400. Similarly, a PEG with an n of 45 has an average weight of about 2000 daltons and is conveniently labeled as PEG 2000.
PEG 3350 is a PEG with a molecular weight of 3350 g/mol. It is commonly used in the pharmaceutical and veterinary industry. The composition of the invention comprises or contains about 5w/w% to about 7w/w% of the total weight of the tablet of at least one binder. The preferred binding agent for the composition of the invention is PEG 3350. The composition further comprises or contains at least one binder that is a gum selected from the group consisting of tragacanth gum, xanthan gum, arabic gum, cellulose gum, guar gum, locust bean gum, or a mixture thereof; and preferably xanthan gum, in the amount of about 0.3w/w% to about 0.7w/w% of the total weight of the , preferably, about 0.4w/w% to about 0.6w/w% of the total weight of the tablet, and more preferably about 0.5w/w% of the total weight of the tablet. The composition comprises or contains about 5w/w% to about 6w/w% of the total weight of the tablet of PEG 3350.
The stable, ble composition comprises or contains at least one veterinary acceptable excipient that is a disintegrant, thereby providing a means for the dosage form to expand and dissolve more readily when wet and/or break apart while being chewed. Disintegrants are conventionally used in direct ssion tablets and are described in Lieberman et al., Veterinary Dosage Forms, 2 Ed., Vol. 1, (1990). Non-exclusive examples of veterinary acceptable disintegrants include: starch including pregelatinized and modified starches, microcrystalline cellulose, methyl cellulose, carboxymethyl cellulose, carboxymethyl ose sodium, crospovidone, magnesium aluminum silicate, guar gum, alginic acid, sodium alginate, calcium alginate, chitosan, croscarmellose sodium (e.g., Ac-Di-Sol®), sodium starch ate, and the like, and mixtures thereof. Preferred disintegrant(s) are selected from the group consisting of , ymethyl ose sodium, crospovidone, croscarmellose sodium, and sodium starch glycolate, and mixtures f. The more preferred disintegrants are sodium starch glycolate and crospovidone, or a e thereof. The most preferred disintegrant is a mixture of crospovidone and sodium starch glycolate. The amount of disintegrant(s) in the composition is about 8w/w% to about 18w/w% of the total weight of the tablet. The preferred amount of disintegrant(s) in the composition is about 10w/w% to about 15w/w% of the total weight of the tablet. The ition comprises or contains about 4w/w% to about 9w/w% of the total weight of the tablet of crospovidone and about 4w/w% to about 9w/w% of the total weight of the tablet of sodium starch glycolate.
The stable, palatable composition comprises or contains at least one veterinary acceptable excipient that is a ant. Humectants are considered hygroscopic in that they impart moisture to the composition. miting examples of humectants for the composition include, but are not limited to: glycerin (glycerol), hyaluronic acid, sorbitol, urea, alpha y acids, , lactic acid, propylene glycol, glyceryl triacetate, lithium chloride, polyols like ol, l and maltitol, polymeric polyols like polydextrose, natural extracts like quillaia, hexadecyl, myristyl, isodecyl and isopropyl esters of adipic, lactic, oleic, stearic, isostearic, ic and linoleic acids, as well as many of their corresponding alcohol esters (e.g. sodium aroyllactylate, sodium capryl lactylate). The preferred humectant is glycerol and is in the amount of about 10w/w% to about 15w/w% of the total weight of the tablet. The preferred amount of humectant is about 11w/w% to about 14w/w% of the total weight of the tablet.
The stable, ble composition comprises or contains at least one veterinary acceptable excipient that is a lubricant. Lubricants are used to enhance product flow by reducing inter-particulate friction and to prevent compositional ingredients from ng together and from sticking to the tablet punches. Lubricants also ensure that tablet formation and on can occur with low friction between the tablet and die wall. miting examples of lubricants include: talc, magnesium stearate, glyceryl monostearate, boric acid, sodium benzoate, sodium olete, sodium acetate, sodium lauryl sulfate, magnesium lauryl sulfate, and mixtures thereof. Preferred lubricants include talc, magnesium stearate, and glyceryl monostearate. The more preferred lubricants are magnesium stearate, glycerol monostearate, and mixtures thereof.
The composition comprises glycerol monostearate and magnesium stearate as lubricants in the amount of about 1 w/w% to about 2w/w% of the total weight of the tablet.
The stable, ble composition comprises or contains at least one veterinary acceptable excipient that is a glidant. Glidants are used to promote powder flow by reducing interparticle friction and cohesion. These are used in combination with lubricants as they have no ability to reduce die wall friction.
Examples include fumed , colloidal silicon dioxide, talc, and magnesium carbonate. The preferred glidant is colloidal silicon dioxide and is in the amount of about 1w/w% to about 3w/w% of the total weight of the tablet. The preferred amount of glidant in the composition is about 1,5w/w% to about 2.5w/w% of the total weight of the tablet.
The stable, ble composition can further comprise or contain at least one veterinary acceptable excipient that is an antioxidant. Non-exclusive examples of antioxidants include: ascorbic acid, n E (tocopherol), n E derivatives, sodium metabisulphate, ascrobyl palmitate, fumaric acid, citric acid, malic acid, sodium ascorbate, butylated hydroxanisole (BHA), and butylated hydroxytoluene (BHT), propyl gallate, thioglycerol, and the like, and mixtures thereof. Preferred antioxidants include BHA, BHT, citric acid, and propyl gallate, and mixtures thereof. The amount of antioxidant(s) in the composition can range from about 0w/w% to about 0.05w/w% of the total weight of the tablet.
The stable, palatable composition can also comprise or contain at least one veterinary acceptable excipient that is a colorant. Colorants can be added to the composition to enhance its physical appearance and can be in the amount of about 1w/w% (or less) of the total weight of the tablet.
The stable, ble composition is prepared as a common blend that can be tableted into ent tablet sizes with the same w/w% values of active agent, palatants, and excipients that can be manufactured by general granulation, blending, milling, sieving, compression, and ing ures.
The composition of the ion can be prepared by known procedures for manufacturing common blends and ing via rotary ssion.
A binder solution is prepared by melting and mixing the binder, PEG 3350, with a lubricant (glyceryl monostearate) and glycerol at a temperature of about 90-100°C to prepare binder solution (A). Alternatively, a second binder solution can be prepared containing solubilized xanthan gum in glycerol to prepare binder on (B). The -flavored dry-blended granulation is prepared by mixing (blending) and granulating the active agent {e.g., oclacitinib maleate) with a palatant, disintegrants, a binder (xanthan gum), flavor modifier, and t in a high shear granulator. The dry blend is milled and then mixed with binder solution (A) to prepare a wet granulation. Alternatively, the activeflavored dry-blended granulation is first mixed with a portion of glycerol prior to on and further mixing with binder solution (A) to prepare the wet granulation. In addition, the active-flavored dry-blended granulation (without binder) can be mixed with binder ons (A) and (B) to prepare the wet granulation. The wet granulation is milled and then cured for about 1 to 3 hours at about 45°C to 65°C in a fluid bed dryer. An extra-granular composition comprising a glidant, a palatant, and disintegrant was prepared by blending the ents together and then milled. The cured active-flavored granulation and extra-granular composition were blended together in a low-shear bin-type blender and a ant is sifted into the blend. The final blend is then compressed using a rotary tablet press. The final tablets were packaged in HOPE bottles and/or blisters.
The finished tablets comprise about w% of the total weight of the tablet of oclacitinib maleate. Depending upon tablet size, preferred tablet strengths are 3.6mg, 5.4mg, and 16.0mg oclacitinib per tablet. Further, tablets can be prepared to have re from 1,2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 7, 18, 19, 20, 21,22, 23, 24, 25mg, and the like, of oclacitinib, including additional fractional amounts, e.g., 2.5, 7. 7, 12.3, 16.6, 22.3, and the like, by altering the size of the tablet die during compression since this composition is a common blend.
The therapeutically effective dose of oclacitinib in dogs is 0.4 to 0.6 mg/kg body weight, administered orally, twice daily for up to 14 days, and then administered once daily for maintenance therapy. Depending upon the weight of the dog, single chewable tablets can be administered, or multiple tablets can be administered to ensure the ive mg/kg dose amount is administered for larger breed dogs. In addition, appropriate dose amounts can be administered to cats, horses, and other animals; these doses may be different and could range from 0.1 to 1 mg/kg body weight depending on the animal and half-life cokinetics of oclacitinib in the non-canine animals.
Average tablet in-process s from the common-blend apoquel chewable composition is shown in Table 1.
Table 1: Tablet In-Process Results from the Apoquel Common Blend Process Parameter Tablet Strength 3.6mg 5.4mg 16mg Weight Uniformity (mg) 119 182 534 Tablet Thickness (mm) 3.78 4.40 5.87 Tablet ss (kp) 2.0 3.3 5.8 Disintegration Time (sec) 150 190 252 FriabilityA 0.237 0.014 0.013 A(%w/w at 100 rotation) Compositional Examples The invention is further described by the ing examples which further illustrate the invention, and is not intended, nor should it be interpreted to, limit the scope of the invention.
Example 1. Tablet Composition 1 Excipient/Active w/w% of Total Tablet Oclacitinib maleate 4.03 Animal based palatant 48.64 Non-animal based palatant 13.13 Disintegrants 11.40 t 2.11 Lubricants 1.34 s 6.07 Humectant 12.72 Flavor modifier 0.56 Total 100 Example 2. Tablet Composition 2 Excipient/Active w/w% of Total Tablet Oclacitinib maleate 4.03 Animal based palatant 48.64 Non-animal based palatant 11.63 Disintegrants 12.90 Glidant 2.11 Lubricants 1.34 Binders 6.07 Humectant 12.72 Flavor modifier 0.56 Total 100 Example 3. Tablet Composition 3 Excipient/Active w/w% of Total Tablet Oclacitinib maleate 4.03 Animal based palatant 48.64 Non-animal based nt 13.63 Disintegrants 11.4 Glidant 1.61 Lubricants 1.34 Binders 6.07 Humectant 12.72 Flavor modifier 0.56 Total 100 Example 4. Tablet Composition 4 Excipient/Active w/w% of Total Tablet Oclacitinib maleate 4.03 Animal based palatant 46.2 Non-animal based palatant 12.5 Disintegrants 13.4 Glidant 1.85 Lubricants 1.70 Binders 6.4 Humectant 13.5 Flavor er 0.42 Total 100 e 5. Tablet Composition 5 Excipient/Active w/w% of Total Tablet Oclacitinib maleate 4.03 Animal based palatant 48.1 Non-animal based palatant 13.8 Disintegrants 13.9 Glidant 1.55 Lubricants 1.04 s 5.2 ant 11.8 Flavor modifier 0.58 Total 100 Biological Palatable soft chew compositions containing oclacitinib maleate were ed and evaluated for palatability and stability.
Palatabilitv To assess palatability, mature 3-9 year old beagle dogs (N=48) were randomly assigned to a 2-sequence, 2-period crossover design study. Animals were offered a placebo (T01) soft chew tablet or a test soft chew tablet containing 5.4mg of Apoquel® (T02-composition 1). One tablet was offered for free oral consumption daily for three utive days for each group of dogs (N=24/group). Acceptability for the placebo (T01) and the Apoquel® (T02) soft chew tablets was 79.9% and 78.5%, respectively.
In another palatability study, mixed breed dogs (N=96) that were >1-year old were randomly assigned to a 4-period crossover design study. Animals were offered placebo (T01) soft chew tablet or a test soft chew tablet containing 5.4mg of Apoquel® [T02-composition 1; T03-composition 2; and T04-composition 3], One tablet was offered for free oral ption daily for three consecutive days for each group of dogs (N=24/group). Acceptability for the placebo and the Apoquel® soft chew tablets was 85% (T01), 84% (T02), 83% (T03), and 83% (T04). Overall, the compositions ning oclacitinib were palatable.
Stability The soft chew tablets were shown to be stable at 1 and 2 months at % relative humidity in HOPE bottles for the 3.6mg, 5.4mg, and 16mg soft chew tablets with assay (% of label claim) results ranging from 98.3 to 101.5%.
Claims (21)
1. A palatable soft le tablet veterinary composition comprising: a. a therapeutically ive amount of a veterinary active agent, wherein the veterinary active agent is oclacitinib or a veterinary acceptable salt thereof; b. at least one animal based palatant in an amount of about 45w/w% to about 55w/w% of the total weight of the tablet; c. at least one non-animal based palatant in an amount of about 10w/w% to about 15w/w% of the total weight of the tablet; d. at least one veterinary acceptable excipient; and wherein the soft-chewable tablet is compressed with a rotary tablet press.
2. The composition of Claim 1, wherein the veterinary acceptable salt is the maleate salt and the animal based palatant is powdered pork liver.
3. The composition of Claim 1 or 2, wherein the at least one veterinary acceptable excipient is selected from at least one each of a disintegrant, binder, humectant, lubricant, glidant, and flavor modifier; and wherein the imal based palatant is yeast.
4. The ition of Claim 3, wherein the veterinary able disintegrant is crospovidone, sodium starch glycolate, or a mixture thereof.
5. The composition of Claim 4, n the disintegrant is a mixture of crospovidone and sodium starch glycolate, and combined are in an amount of about 10w/w% to about 15w/w% of the total weight of the tablet.
6. The composition of any one of Claims 3 to 5, wherein the nary acceptable binder comprises polyethylene glycol, a gum, or a mixture thereof.
7. The composition of Claim 6, wherein the polyethylene glycol is polyethylene glycol 3350 and the gum is xanthan gum and wherein the mixture of polyethylene glycol and the gum ses about 5w/w% to about 7w/w% of the total weight of the tablet.
8. The composition of any one of Claims 3 to 7, wherein the nary acceptable humectant is glycerol in an amount of about 10w/w% to about 15w/w% of the total weight of the tablet.
9. The composition of any one of Claims 3 to 8, wherein the veterinary acceptable lubricant is a mixture of magnesium stearate and glycerol monostearate in an amount of about 1w/w% to about 2w/w%, and wherein the composition comprises about 1w/w% to about 3w/w% of a glidant and about 0.4w/w% to about % of a flavor modifier.
10. A palatable soft chewable tablet veterinary composition comprising: a. a therapeutically effective amount of oclacitinib maleate that is in an amount of about 4w/w% to about 5w/w% of the total weight of the tablet; b. an animal based palatant that is derived from pork liver; c. a non-animal based palatant that is Brewer’s yeast; d. a mixture of veterinary acceptable excipients, that is one each of a disintegrant, binder, humectant, lubricant, t, and flavor modifier; and wherein the soft chewable tablet is compressed with a rotary tablet press.
11. The composition of Claim 10, wherein the pork liver is powdered and is in an amount of about 46w/w% to about 52w/w% of the total weight of the tablet and the ’s yeast is in an amount of about 11w/w% to about 14w/w% of the total weight of the tablet.
12. The composition of Claim 10 or 11, wherein the disintegrant is selected from the group consisting of vidone, sodium starch glycolate, or e thereof, and is in an amount of about 10w/w% to about 15w/w% of the total weight of the tablet; the binder is selected from the group consisting of hylene glycol 3350, xanthan gum, or mixture thereof, and is in an amount of about 5w/w% to about 7w/w% of the total weight of the tablet; the humectant is glycerol and is in an amount of about 11w/w% to about 14w/w% of the total weight of the tablet; the lubricant is selected from the group ting of magnesium stearate, glycerol monostearate, or mixture thereof, and is in an amount of about 1w/w% to about 2w/w% of the total weight of the tablet; the glidant is colloidal silicon dioxide in an amount of about 1w/w% to about 3w/w% of the total weight of the tablet; and the flavor modifier is sodium chloride in an amount of about 0.4w/w% to 0.6w/w% of the total weight of the tablet
13. A palatable soft chewable tablet veterinary composition comprising: a. a therapeutically effective amount of oclacitinib maleate in an amount of about 4w/w% of the total weight of the tablet; b. a e of palatants in an amount of about 55w/w% to about 70w/w% of the total weight of the tablet comprising an animal based palatant and a non-animal based palatant; c. a mixture of binders in an amount of about 5w/w% to about 7w/w% of the total weight of the tablet ed from hylene glycol 3350 and xanthan gum; d. a mixture of disintegrants in an amount of about 8w/w% to about 18w/w% of the total weight of the tablet comprising crospovidone and sodium starch glycolate; e. the humectant glycerol in an amount of about 11w/w% to about 14w/w% of the total weight of the tablet; f. a flavor modifier that is sodium chloride in an amount of about 0.4w/w% to about % of the total weight of the tablet; g. a glidant that is colloidal silicon dioxide in an amount of about 1w/w% to about 3w/w% of the total weight of the table; and wherein the soft chewable tablet is compressed on a rotary tablet press.
14. The composition of Claim 1, wherein the composition ses: Oclacitinib maleate 4.03 w/w% of the total weight of the tablet Animal based palatant 48.64 w/w% of the total weight of the tablet Non-animal based palatant 13.13 w/w% of the total weight of the tablet Disintegrants 11.40 w/w% of the total weight of the tablet Glidant 2.11 w/w% of the total weight of the tablet Lubricants 1.34 w/w% of the total weight of the tablet s 6.07 w/w% of the total weight of the tablet Humectant 12.72 w/w% of the total weight of the tablet Flavor modifier 0.56 w/w% of the total weight of the tablet.
15. The composition of Claim 1, wherein the composition comprises: Oclacitinib maleate 4.03 w/w% of the total weight of the tablet Animal based palatant 48.64 w/w% of the total weight of the tablet Non-animal based palatant 11.63 w/w% of the total weight of the tablet Disintegrants 12.90 w/w% of the total weight of the tablet Glidant 2.11 w/w% of the total weight of the tablet Lubricants 1.34 w/w% of the total weight of the tablet Binders 6.07 w/w% of the total weight of the tablet Humectant 12.72 w/w% of the total weight of the tablet Flavor modifier 0.56 w/w% of the total weight of the tablet.
16. The composition of Claim 1, wherein the composition ses: Oclacitinib maleate 4.03 w/w% of the total weight of the tablet Animal based palatant 48.64 w/w% of the total weight of the tablet Non-animal based palatant 13.63 w/w% of the total weight of the tablet Disintegrants 11.4 w/w% of the total weight of the tablet Glidant 1.61 w/w% of the total weight of the tablet Lubricants 1.34 w/w% of the total weight of the tablet Binders 6.07 w/w% of the total weight of the tablet ant 12.72 w/w% of the total weight of the tablet Flavor modifier 0.56 w/w% of the total weight of the tablet.
17. The composition of Claim 1, wherein the composition comprises: Oclacitinib maleate 4.03 w/w% of the total weight of the tablet Animal based palatant 46.2 w/w% of the total weight of the tablet Non-animal based nt 12.5 w/w% of the total weight of the tablet Disintegrants 13.4 w/w% of the total weight of the tablet Glidant 1.85 w/w% of the total weight of the tablet Lubricants 1.70 w/w% of the total weight of the tablet s 6.4 w/w% of the total weight of the tablet Humectant 13.5 w/w% of the total weight of the tablet Flavor modifier 0.42 w/w% of the total weight of the tablet.
18. The composition of Claim 1, wherein the composition comprises: Oclacitinib maleate 4.03 w/w% of the total weight of the tablet Animal based palatant 48.1 w/w% of the total weight of the tablet Non-animal based palatant 13.8 w/w% of the total weight of the tablet Disintegrants 13.9 w/w% of the total weight of the tablet Glidant 1.55 w/w% of the total weight of the tablet Lubricants 1.04 w/w% of the total weight of the tablet Binders 5.2 w/w% of the total weight of the tablet Humectant 11.8 w/w% of the total weight of the tablet Flavor modifier 0.58 w/w% of the total weight of the tablet.
19. A method for the treatment or prevention of a cancer, asthma, atopic dermatitis, autoimmune disorders, pruritus associated with allergic dermatitis, allergy, or chronic respiratory disease associated with JAK in a companion animal, the method sing administering an effective amount of a palatable soft chewable tablet veterinary ition of any one of Claims 1 to 18 to the companion animal.
20. The method of Claim 19, for the treatment or prevention of pruritis associated with ic dermatitis and atopic itis in a companion animal that is a dog.
21. The composition of any one of Claims 1, 10 or 13, substantially as herein described with reference to any one of the examples thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962807871P | 2019-02-20 | 2019-02-20 | |
PCT/US2020/018762 WO2020172232A1 (en) | 2019-02-20 | 2020-02-19 | Palatable formulations |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ779157A NZ779157A (en) | 2023-10-27 |
NZ779157B2 true NZ779157B2 (en) | 2024-01-30 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2020224102B2 (en) | Palatable formulations | |
US9381155B2 (en) | Process for manufacturing chewable dosage forms for drug delivery and products thereof | |
EP2063868B1 (en) | Pharmaceutical compositions containing rosuvastatin calcium | |
JP7412329B2 (en) | Oral composition and method for preparing the same | |
US20090280159A1 (en) | Process for manufacturing chewable dosage forms for drug delivery and products thereof | |
CN108685894A (en) | Soft chewing medicinal product | |
WO2013068371A1 (en) | Soft chewable dosage form compositions of cannabinoid receptor type 1 (cb-1) antagonists | |
RU2789487C1 (en) | Dosage forms with a pleasant taste | |
NZ779157B2 (en) | Palatable formulations | |
AU778538B2 (en) | Method and composition for administering a cyclooxygenase-2 inhibitor | |
US20040097549A1 (en) | Method and composition for administering a cyclooxygenase-2 inhibitor | |
WO2002100409A1 (en) | Antiinflammatoric and antitussive compositions | |
EA027817B1 (en) | Dosage form comprising a solid ambroxol-containing formulation and use thereof |